$1,200
total
52 weeks
Duration
10
Total Visits
177
Spots Remaining
About This Study
This clinical trial evaluates a new biologic medication that targets specific immune pathways involved in psoriasis. The treatment is administered as a subcutaneous injection every 8 weeks after initial loading doses.
Study Objectives
To determine the proportion of patients achieving 90% improvement in PASI score at week 16.
Eligibility Requirements
Inclusion Criteria
- Adults 18 years and older
- Moderate-to-severe plaque psoriasis for at least 6 months
- Body Surface Area involvement of 10% or greater
- PASI score of 12 or higher
- Candidate for systemic therapy
Exclusion Criteria
- Active infections
- History of tuberculosis
- Prior biologic treatment in last 3 months
- Pregnancy or planning pregnancy
Frequently Asked Questions
Study Location
Northwestern Memorial Hospital
Chicago, IL 60611
Map View
Research Team
Dr. Amanda Foster
Northwestern University Feinberg School of Medicine
Dermatology Clinical Trials
Study Timeline
Start DateFebruary 15, 2024
End DateJune 30, 2025
Enrollment423 / 600